Doxylamine succinate (CAS 562-10-7) is a high-purity, pharmaceutical-grade antihistamine synthesized through refined chemical processes, strictly complying with USP, EP, and CP quality standards. Its molecular structure features a stable succinate salt form, ensuring excellent water solubility and bioavailability, which facilitates rapid absorption in the human body. With rigorous impurity control (total impurities ≤ 0.1%) and consistent batch-to-batch performance, this compound serves as a reliable raw material for pharmaceutical formulation, standing out for its stable chemical properties and proven efficacy.
As a first-generation antihistamine, it exerts potent anti-allergic, sedative, and hypnotic effects by blocking histamine H1 receptors. It effectively alleviates symptoms of allergic rhinitis such as sneezing, runny nose, and itchy eyes, while also aiding in the relief of insomnia and sleep disturbances due to its mild sedative property. Unlike some synthetic antihistamines, it has a well-documented safety profile and low risk of severe side effects, making it suitable for both over-the-counter and prescription drug development. Additionally, it demonstrates good compatibility with other pharmaceutical excipients, supporting diverse formulation forms like tablets, capsules, and syrups.
Doxylamine succinate (CAS 562-10-7) caters to various professional needs, ranging from pharmaceutical manufacturers producing anti-allergic and sleep-aid medications to research institutions conducting studies on histamine receptor antagonists. Its pharmaceutical-grade purity, multi-functional efficacy, and compliance with international quality standards make it a top choice for buyers prioritizing reliability and performance. Whether for large-scale commercial production or small-batch scientific experiments, this antihistamine consistently meets the stringent requirements of the global pharmaceutical industry.
